|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| The Use of Genomics in Unfavorable Intermediate-risk Prostate Cancer |
| David Morris, MD |
| David Morris joins Ashley Ross in a conversation on genomics in prostate cancer specifically, in the unfavorable intermediate-risk patient. Drs Morris and Ross highlight the use of genomics in decision-making when considering what the best treatment option is for this group of individuals. They are particularly interested in determining if any of these intermediate-risk patients might actually be higher risk or lower risk than expected. |
|
|
|
|
|
|
|
|
|
|
|
| Treatment of Unfavorable Intermediate Risk Prostate Cancer |
Jason Hafron, MD, and Katie S. Murray, DO, MS, FACS
Jason Hafron and Katie Murray join Ashley Ross in a conversation on the treatment of unfavorable intermediate-risk prostate cancer and the value of the genomic classifier useful in guiding treatment considerations. |
|
|
|
|
|
|
|
|
|
|
| Decipher Biopsy and Decipher for Prostatectomy in Clinical Practice |
Ashley Ross, MD, Ph.D.
Alicia Morgans and Ashley Ross discuss Decipher testing, both Decipher Biopsy and Decipher for prostatectomy specimens, and how to integrate these tests into standard clinical practice. Decipher is a genomic classifier that looks at the whole genome and expression patterns on that genome. The genomic classifier score is a prognostic score that goes from 0 to 1, and it was first developed to stratify the risk of metastatic progression following prostatectomy. |
|
|
|
|
|
|
|
|
|
|
| How Can Treatment Be Individualized By Using Genomic Classifiers? |
| Felix Feng, MD
|
| The 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting included a session on biochemical recurrence, and a presentation by Dr. Felix Feng discussing how treatment can be individualized by using genomic classifiers. Dr. Feng started by highlighting that genomic biomarkers are included in certain treatment guidelines for the management of PSA recurrences. In the NCCN guidelines, the Decipher molecular assay is recommended for risk stratification among men with PSA persistence or recurrence.
|
|
|
|
|
|
|
|
|
|
|
| Validation of the Performance of the Decipher Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer in the Phase III Randomized Trial NRG Oncology/RTOG 0126 |
| Daniel Spratt, MD |
| Dan Spratt presents a poster outlining validation of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer. The 22-gene Decipher genomic classifier (GC) is a prognostic biomarker that has been validated in phase III trials in high-risk localized, post-prostatectomy, and metastatic and non-metastatic castration-resistant prostate cancer. |
|
|
|
|
|
| A High-Risk Decipher Biopsy Score is Associated with Conversion from Active Surveillance to Treatment and Treatment Failure in Localized Prostate Cancer - Beyond the Abstract |
| Udit Singhal, MD and Randy A. Vince Jr., MD, MS |
| Genomic classifiers are used for prognostication and risk stratification in prostate cancer. Despite the emerging data, a commonly cited limitation is the retrospective datasets used for analysis. While there has been a litany of data using retrospective datasets to extrapolate the value of commercially available platforms in the pretreatment setting, the evaluation of these assays using prospectively collected data is still needed. |
|
|
|
|
|
|
|
|
|
|
|
